Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G.

doi:10.1093/oncolo/oyae119

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G.

The oncologist - 5 Aug 2024

Nelson Marie V, Kim AeRang, Williams P Mickey, Roy-Chowdhuri Sinchita, Patton David R, Coffey Brent D, Reid Joel M, Piao Jin, Saguilig Lauren, Alonzo Todd A, Berg Stacey L, Ramirez Nilsa C, Jaju Alok, Fox Elizabeth, Weigel Brenda J, Hawkins Douglas S, Mooney Margaret M, Takebe Naoko, Tricoli James V, Janeway Katherine A, Seibel Nita L, Parsons D Williams

Abstract excerpt

BACKGROUND: This is a phase II subprotocol of the NCI-COG Pediatric MATCH study evaluating vemurafenib, a selective oral inhibitor of BRAF V600 mutated kinase, in patients with relapsed or refractory solid tumors harboring BRAF V600 mutations. METHODS: Patients received vemurafenib at 550 mg/m2 (maximum 960 mg/dose) orally twice daily for 28-day cycles until progression or intolerable toxicity. The primary aim...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child

Share to Child, Preschool

Share to Mutation

Share to Neoplasms

Share to Proto-Oncogene Proteins B-raf

Share to Vemurafenib

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 38873934
DOI: 10.1093/oncolo/oyae119
PMCID: PMC11299954

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G.PMID 38873934Read ↗

BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma.Semantic proximity Read ↗

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.Semantic proximity Read ↗

Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas.Semantic proximity Read ↗

Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.Semantic proximity Read ↗

Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trialSemantic proximity Read ↗

Type II RAF inhibitor tovorafenib for the treatment of pediatric low-grade glioma.Semantic proximity Read ↗

Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations.Semantic proximity Read ↗

Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium.Semantic proximity Read ↗

LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.Semantic proximity Read ↗

Efficacy and Safety of Dabrafenib in Pediatric Patients with <i>BRAF</i> V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa StudySemantic proximity Read ↗

Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas.Semantic proximity Read ↗

Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.